News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
151,675 Results
Type
Article (4845)
Company Profile (51)
Press Release (146779)
Multimedia
Podcasts (4)
Webinars (2)
Section
Business (51078)
Career Advice (153)
Deals (10137)
Drug Delivery (19)
Drug Development (17694)
Employer Resources (16)
FDA (3912)
Job Trends (4142)
News (81801)
Policy (5974)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Standard (1)
Academia (423)
Academic (1)
Accelerated approval (7)
Adcomms (2)
Allergies (49)
Alliances (6785)
ALS (42)
Alzheimer's disease (410)
Antibody-drug conjugate (ADC) (67)
Approvals (4110)
Artificial intelligence (80)
Autoimmune disease (36)
Automation (7)
Bankruptcy (50)
Best Places to Work (3777)
BIOSECURE Act (3)
Biosimilars (57)
Biotechnology (16)
Bladder cancer (80)
Brain cancer (20)
Breast cancer (201)
Cancer (1448)
Cardiovascular disease (132)
Career advice (134)
Career pathing (5)
CAR-T (49)
CDC (4)
Cell therapy (147)
Cervical cancer (7)
Clinical research (16441)
Collaboration (294)
Company closure (2)
Compensation (142)
Complete response letters (10)
COVID-19 (501)
CRISPR (21)
C-suite (92)
Cystic fibrosis (21)
Data (2100)
Decentralized trials (2)
Depression (27)
Diabetes (138)
Diagnostics (1747)
Digital health (11)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (45)
Drug pricing (29)
Drug shortages (4)
Duchenne muscular dystrophy (59)
Earnings (40687)
Editorial (12)
Employer branding (1)
Employer resources (15)
Events (21147)
Executive appointments (105)
FDA (4984)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (235)
Gene editing (36)
Generative AI (9)
Gene therapy (110)
GLP-1 (196)
Government (766)
Grass and pollen (2)
Guidances (298)
Healthcare (4673)
HIV (26)
Huntington's disease (20)
IgA nephropathy (29)
Immunology and inflammation (67)
Immuno-oncology (14)
Indications (35)
Infectious disease (583)
Inflammatory bowel disease (43)
Inflation Reduction Act (1)
Influenza (34)
Intellectual property (37)
Interviews (17)
IPO (6574)
IRA (6)
Job creations (578)
Job search strategy (118)
JPM (16)
Kidney cancer (7)
Labor market (18)
Layoffs (98)
Leadership (3)
Legal (1227)
Liver cancer (24)
Longevity (3)
Lung cancer (219)
Lymphoma (157)
Machine learning (4)
Management (10)
Manufacturing (129)
MASH (64)
Medical device (3184)
Medtech (3194)
Mergers & acquisitions (3855)
Metabolic disorders (325)
Multiple sclerosis (45)
NASH (8)
Neurodegenerative disease (78)
Neuropsychiatric disorders (13)
Neuroscience (726)
NextGen: Class of 2026 (1376)
Non-profit (1080)
Now hiring (4)
Obesity (116)
Opinion (25)
Ovarian cancer (49)
Pain (45)
Pancreatic cancer (47)
Parkinson's disease (90)
Partnered (9)
Patents (76)
Patient recruitment (76)
Peanut (19)
People (5506)
Pharmaceutical (15)
Pharmacy benefit managers (12)
Phase 1 (4095)
Phase 2 (6669)
Phase 3 (6728)
Pipeline (2248)
Policy (34)
Postmarket research (716)
Preclinical (1323)
Press Release (8)
Prostate cancer (79)
Psychedelics (5)
Radiopharmaceuticals (60)
Rare diseases (203)
Real estate (965)
Recruiting (5)
Regulatory (5047)
Reports (9)
Research institute (435)
Resumes & cover letters (23)
Rett syndrome (7)
RNA editing (3)
RSV (27)
Schizophrenia (42)
Series A (35)
Series B (33)
Service/supplier (3)
Sickle cell disease (28)
Special edition (11)
Spinal muscular atrophy (28)
Sponsored (9)
Startups (412)
Stomach cancer (5)
Supply chain (20)
Tariffs (14)
The Weekly (4)
Vaccines (222)
Venture capital (18)
Weight loss (78)
Women's health (24)
Worklife (1)
Date
Today (11)
Last 7 days (164)
Last 30 days (597)
Last 365 days (8556)
2026 (995)
2025 (8792)
2024 (9040)
2023 (10283)
2022 (11699)
2021 (13647)
2020 (12697)
2019 (10987)
2018 (8218)
2017 (6921)
2016 (5750)
2015 (7782)
2014 (5287)
2013 (3907)
2012 (4391)
2011 (5080)
2010 (4233)
Location
Africa (114)
Alabama (15)
Alaska (1)
Arizona (52)
Arkansas (3)
Asia (8756)
Australia (1207)
California (3108)
Canada (718)
China (253)
Colorado (126)
Connecticut (163)
Delaware (147)
Europe (19665)
Florida (462)
Georgia (101)
Hawaii (1)
Idaho (16)
Illinois (255)
India (21)
Indiana (170)
Iowa (10)
Japan (123)
Kansas (42)
Kentucky (7)
Louisiana (15)
Maine (21)
Maryland (327)
Massachusetts (2289)
Michigan (81)
Minnesota (172)
Mississippi (2)
Missouri (48)
Montana (2)
Nebraska (3)
Nevada (27)
New Hampshire (13)
New Jersey (1225)
New Mexico (4)
New York (874)
North Carolina (396)
North Dakota (2)
Northern California (1591)
Ohio (69)
Oklahoma (1)
Oregon (6)
Pennsylvania (578)
Puerto Rico (2)
Rhode Island (15)
South America (167)
South Carolina (4)
Southern California (1239)
Tennessee (41)
Texas (401)
United States (11423)
Utah (191)
Vermont (1)
Virginia (64)
Washington D.C. (23)
Washington State (227)
West Virginia (1)
Wisconsin (28)
151,675 Results for "80".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
JPM26: AstraZeneca’s Path to $80B by 2030 Paved With ADCs, Cell Therapies, Near-Term Launches
AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs for hypertension, breast cancer and generalized myasthenia gravis, all of which are currently under FDA review.
January 14, 2026
·
2 min read
·
Tristan Manalac
Press Releases
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
February 18, 2026
·
6 min read
Press Releases
Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096
February 19, 2026
·
7 min read
Startups
Corsera Raises $80M as First Preventative Heart Disease Program Moves Into Clinic
The cardiovascular biotech was also named as one of
BioSpace
’s top startups to watch on Wednesday.
January 7, 2026
·
1 min read
·
Annalee Armstrong
Press Releases
Corsera Health Announces $80 Million Series A Financing and Reaches Key Clinical Milestone
January 8, 2026
·
5 min read
Press Releases
Proxima Raises $80 Million Led by DCVC to Power the Next Generation of Proximity-Based Medicines
January 13, 2026
·
3 min read
Press Releases
Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
January 9, 2026
·
1 min read
Press Releases
GRI Bio Announces Closing of $8.0 Million Public Offering
December 15, 2025
·
6 min read
Press Releases
Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
January 8, 2026
·
9 min read
Press Releases
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
January 7, 2026
·
5 min read
1 of 15,168
Next
